Article
A Phase II Study of Cabozantinib in Metastatic or Unresectable Refractory Gastrointestinal Stromal Tumour: A Single-Centre Study from India
2026-03-19
Abstract excerpt
<title>Abstract</title> <p> <bold>Background:</bold> Beyond third-line therapy, options for metastatic/advanced GIST are limited, especially in low- and middle-income countries (LMICs) where access to fourth-line ripretinib is often restricted. Cabozantinib, a multi-kinase inhibitor targeting KIT and related resistance pathways, could serve as a pragmatic alternative. This Phase II study evaluated the efficacy...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 3478d6b4-b5a1-5811-8f8b-4f9bebee282b
- DOI
- 10.21203/rs.3.rs-8910891/v1